INTRODUCTION: We compared the sensitivity and specificity of T2*-weighted gradient-echo imaging (T2*-GRE) and susceptibility-weighted imaging (SWI) in determining prevalence and cumulative incidence of intratumoral hemorrhages in children with diffuse intrinsic pontine glioma (DIPG) undergoing antiangiogenic and radiation therapy. METHODS: Patients were recruited from an institutional review board-approved prospective phase I trial of vandetanib administered in combination with radiation therapy. Patient consent was obtained before enrollment. Consecutive T2*-GRE and SWI exams of 17 patients (F/M: 9/8; age 3-17 years) were evaluated. Two reviewers (R1 and R2) determined the number and size of hemorrhages at baseline and multiple follow-ups (92 scans, mean 5.4/patient). Statistical analyses were performed using descriptive statistics, graphical tools, and mixed-effects Poisson regression models. RESULTS: Prevalence of hemorrhages at diagnosis was 41% and 47%; the cumulative incidences of hemorrhages at 6 months by T2*-GRE and SWI were 82% and 88%, respectively. Hemorrhages were mostly petechial; 9.7% of lesions on T2*-GRE and 5.2% on SWI were hematomas (>5 mm). SWI identified significantly more hemorrhages than T2*-GRE did. Lesions were missed or misinterpreted in 36/39 (R1/R2) scans by T2*-GRE and 9/3 scans (R1/R2) by SWI. Hemorrhages had no clinically significant neurological correlates in patients. CONCLUSIONS: SWI is more sensitive than T2*-GRE in detecting hemorrhages and differentiating them from calcification, necrosis, and artifacts. Also, petechial hemorrhages are more common in DIPG at diagnosis than previously believed and their number increases during the course of treatment; hematomas are rare.
INTRODUCTION: We compared the sensitivity and specificity of T2*-weighted gradient-echo imaging (T2*-GRE) and susceptibility-weighted imaging (SWI) in determining prevalence and cumulative incidence of intratumoral hemorrhages in children with diffuse intrinsic pontine glioma (DIPG) undergoing antiangiogenic and radiation therapy. METHODS:Patients were recruited from an institutional review board-approved prospective phase I trial of vandetanib administered in combination with radiation therapy. Patient consent was obtained before enrollment. Consecutive T2*-GRE and SWI exams of 17 patients (F/M: 9/8; age 3-17 years) were evaluated. Two reviewers (R1 and R2) determined the number and size of hemorrhages at baseline and multiple follow-ups (92 scans, mean 5.4/patient). Statistical analyses were performed using descriptive statistics, graphical tools, and mixed-effects Poisson regression models. RESULTS: Prevalence of hemorrhages at diagnosis was 41% and 47%; the cumulative incidences of hemorrhages at 6 months by T2*-GRE and SWI were 82% and 88%, respectively. Hemorrhages were mostly petechial; 9.7% of lesions on T2*-GRE and 5.2% on SWI were hematomas (>5 mm). SWI identified significantly more hemorrhages than T2*-GRE did. Lesions were missed or misinterpreted in 36/39 (R1/R2) scans by T2*-GRE and 9/3 scans (R1/R2) by SWI. Hemorrhages had no clinically significant neurological correlates in patients. CONCLUSIONS: SWI is more sensitive than T2*-GRE in detecting hemorrhages and differentiating them from calcification, necrosis, and artifacts. Also, petechial hemorrhages are more common in DIPG at diagnosis than previously believed and their number increases during the course of treatment; hematomas are rare.
Authors: R R Smith; R A Zimmerman; R J Packer; D B Hackney; L T Bilaniuk; L N Sutton; H I Goldberg; R I Grossman; L Schut Journal: Neuroradiology Date: 1990 Impact factor: 2.804
Authors: R J Packer; J M Boyett; R A Zimmerman; L B Rorke; A M Kaplan; A L Albright; M T Selch; J L Finlay; G D Hammond; W M Wara Journal: Cancer Date: 1993-08-15 Impact factor: 6.860
Authors: Karen A Tong; Stephen Ashwal; Barbara A Holshouser; Joshua P Nickerson; Christopher J Wall; Lori A Shutter; Renatta J Osterdock; E M Haacke; Daniel Kido Journal: Ann Neurol Date: 2004-07 Impact factor: 10.422
Authors: R N K Nandigam; A Viswanathan; P Delgado; M E Skehan; E E Smith; J Rosand; S M Greenberg; B C Dickerson Journal: AJNR Am J Neuroradiol Date: 2008-11-11 Impact factor: 3.825
Authors: Deborah T Blumenthal; Orna Aisenstein; Idan Ben-Horin; Dafna Ben Bashat; Moran Artzi; Benjamin W Corn; Andrew A Kanner; Zvi Ram; Felix Bokstein Journal: J Neurooncol Date: 2015-05-05 Impact factor: 4.130
Authors: James L Leach; James Roebker; Austin Schafer; Joshua Baugh; Brooklyn Chaney; Christine Fuller; Maryam Fouladi; Adam Lane; Renee Doughman; Rachid Drissi; Mariko DeWire-Schottmiller; David S Ziegler; Jane E Minturn; Jordan R Hansford; Stacie S Wang; Michelle Monje-Deisseroth; Paul G Fisher; Nicholas G Gottardo; Hetal Dholaria; Roger Packer; Katherine Warren; Sarah E S Leary; Stewart Goldman; Ute Bartels; Cynthia Hawkins; Blaise V Jones Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: S Chawla; I Kister; J Wuerfel; J-C Brisset; S Liu; T Sinnecker; P Dusek; E M Haacke; F Paul; Y Ge Journal: AJNR Am J Neuroradiol Date: 2016-03-24 Impact factor: 3.825
Authors: F Rodjan; P de Graaf; P van der Valk; T Hadjistilianou; A Cerase; P Toti; M C de Jong; A C Moll; J A Castelijns; P Galluzzi Journal: AJNR Am J Neuroradiol Date: 2014-12-18 Impact factor: 3.825
Authors: Stephen Harward; S Harrison Farber; Michael Malinzak; Oren Becher; Eric M Thompson Journal: Childs Nerv Syst Date: 2017-11-18 Impact factor: 1.475